• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
  • Issues
    • Current Issue
    • Issue Archives
  • Editor's Update
  • Advertise
  • Reprints
  • Authors
    • Author Instructions
    • Submission Portal
  • Reviewers
  • Contact

Search

Volume 8 - Issue 11 - November 2011

Case Files with Dr. George »

Hybrid Endovascular and Surgical Approach to Management of Comple­x Iliofemoral Disease

By:

Jon C. George, MD, Riyaz Bashir, MD, Andrew B. Roberts, MD

Abstract

Current guidelines favor a surgical approach for treatment of complex peripheral arterial disease that is diffuse and severe in nature. However, standard open surgical therapies, although durable, are associated with increased perioperative morbidity. Hybrid procedures allow patients, who are poor candidates for surgery, to undergo a limited surgical endarterectomy combined with endovascular treatment under conscious sedation for complete revascularization with significantly lower risk. Herein, we present a successful hybrid procedure of endovascular iliac repair via brachial access combined with a surgical common femoral endarterectomy for a patient who was deemed high-risk for extensive vascular surgery.

VASCULAR DISEASE MANAGEMENT 2011;8:E179–E181

Read the full story »

Clinical Review »

Management of Venous Disease in Patients with Thrombophilia

By:

Amir F. Azarbal, MD, and Timothy K. Liem, MD

Abstract

Venous disease encompasses a wide spectrum of clinical pathology. Thrombophilias are acquired and inherited hypercoagulable conditions that are prevalent among patients with various manifestations of venous disease. However, treatment guidelines often do not investigate the effect of thrombophilia on treatment outcomes. We aim to review the evidence for the relationship between thrombophilias and venous disease, and highlight situations in which the presence of thrombophilia may affect treatment options and outcomes.

VASCULAR DISEASE MANAGEMENT 2011;8:E182–E186

Read the full story »

Original Research »

Cool Excimer Laser-Assisted Angioplasty vs Tibial Balloon Angioplasty in Management of Infragenicular Tibial Arterial Occlusion in Critical Lower Limb Ischemia TASC D

By:

Sherif Sultan, MD, Wael Tawfick, MD, Niamh Hynes, MD

Abstract

Endovascular revascularization (EVAR) is the current gold standard and first line of therapy for critical limb ischemia (CLI). However, despite the advances of EVAR, there is still concern about its capability for treating complex tibial lesions. This study aims to compare outcomes with cool excimer laser-assisted angioplasty (CELA) vs tibial balloon angioplasty (TBA) in patients with CLI TASC D.

Read the full story »

Interview »

Q&A with Dr. Lowell S. Kabnick, MD, About the New VenaCure 1470 nm Laser for the Treatment of Varicose Veins

By:

Interview by Amanda Wright

Tell me about the latest advances in endovascular laser therapy for varicose veins.

There have been 2 major advances in endovascular laser therapy for varicose veins. First is the advent of lasers using 1470 nm and other water-specific wavelengths. Second is the use of jacket-tip laser fibers.

Read the full story »

  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Tara Fields, Classified Sales Manager
    (800) 237-7285, ext. 259

vdm Blogs

EVAR found superior to open AAA repair for long-term survival in Medicare patients: Another nail in open surgery’s coffin?

Frank J Criado MD FACS FSVM

Aneurysms and Cancer: Which comes first in the endovascular era?

Ross Milner MD FACS

What is the best therapy when we compare current data for revascularization of the SFA?

Lawrence A. Garcia MD

When a Patient Presents with an Ulcer, Take a Careful History

Richard R. Heuser MD FACC FACP FESC FSCAI

Long-term results with bare-metal LifeStent in the SFA: Is this bad news for DES technologies?

Frank J Criado MD FACS FSVM
more »

Vascular Newswire

  • Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe
    Thu, 05/17/12 - 10:22am
  • Abbott's XIENCE PRIME and XIENCE V Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
    Wed, 05/16/12 - 9:26am
  • Hospital Mortality Rates for Cardiovascular Revascularization Patients Varies Significantly by State
    Tue, 05/15/12 - 9:31am
  • Boston Scientific Announces CE Mark and European Launch of Innova Self-expanding Bare-metal Stent System
    Mon, 05/14/12 - 12:07pm
more »

Clinical Events Calendar

  • EuroPCR 2012
    Tue, 05/15/2012 - Fri, 05/18/2012
    Paris, France
  • International Vein Congress (IVC) 2012
    Thu, 05/31/2012 - Sun, 06/03/2012
    Miami Beach, FL, United States
  • New Cardiovascular Horizons (NCVH)
    Wed, 06/06/2012 - Sat, 06/09/2012
    New Orleans, LA, United States
more »

Poll

The current focus to decrease the profile size of aortic stent-grafts: :
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2012 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2012 HMP Communications